中国创新药对外授权年交易额突破千亿美元 4年增长近10倍

Group 1 - In 2025, Chinese biopharmaceutical companies achieved a record high in outbound licensing deals, surpassing $137.7 billion, nearly a tenfold increase from 2021, with 186 transactions [1] - Major global pharmaceutical companies, including Novartis, AstraZeneca, and GSK, signed significant agreements with Chinese firms last year [1] - Tom Barsha from Bank of America Securities predicts that the total value of these licensing deals could double again in the next 18 to 24 months, as global companies focus on finding next-generation innovative drug pipelines in China [1] Group 2 - AstraZeneca announced a collaboration with China’s CSPC Pharmaceutical Group, potentially worth up to $18.5 billion, to develop a next-generation GLP-1 class weight loss therapy [2] - The average deal size for outbound licensing by Chinese pharmaceutical companies has reached $1.3 billion this year, a 76% increase from 2025 and six times the average level of 2021 [2] - Macquarie Capital analysts noted that many multinational companies view China as a crucial part of their global R&D infrastructure, especially as they face patent cliffs and seek to reduce costs [2]